IL23A and psoriasis vulgaris: Tildrakizumab is a humanized IgG1 κ monoclonal antibody targeting the p19 subunit of IL-23 and is currently approved for the treatment of moderate-to-severe plaque psoriasis in patients eligible for systemic therapy [26,27,28].